Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1419-1424

  Zhou, Yuefen ^a   Li, Lian Sheng ^a   Dragovich, Peter S ^a   Murphy, Douglas E ^a   Tran, Chinh V ^a   Ruebsam, Frank ^a   Webber, Stephen E ^a   Shah, Amit M ^a   Tsan, Mei ^a   Averill, April ^a   Showalter, Richard E ^a   Patel, Rupal ^a   Han, Qing ^a   Zhao, Qiang ^a   Hermann, Thomas ^a   Kissinger, Charles R ^a   LeBrun, Laurie ^a   Sergeeva, Maria V ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 Hydroxy 3(2H) pyridazinone derivatives; Hepatitis C virus (HCV); Non nucleoside NS5B inhibitors; Pyridazinones; RNA dependent RNA polymerase (RdRp); Small molecule; Structure based design

Indexed keywords

ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE ALPHA; PYRIDAZINONE DERIVATIVE; VIRUS ENZYME;

ARTICLE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STABILITY; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C VIRUS; PHARMACOGENETICS; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG STABILITY; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MODELS, MOLECULAR; PYRIDAZINES; RNA REPLICASE; THIADIAZINES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 38949163316     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.005     Document Type: Article

References (17)

1. Wong T., and Lee S.S. CMAJ 174 (2006) 649
2. Hoofnagle J.H., and Seeff L.B. N. Engl. J. Med. 355 (2007) 2444
3. Koch U., and Narjes F. Curr. Top. Med. Chem. 7 (2007) 1302
4. Zhou Y., Webber S.E., Murphy D.E., Li L.-S., Dragovich P.S., Tran C.V., Sun Z., Ruebsam F., Shah A.M., Tsan M., Showalter R.E., Patel R., Li B., Zhao Q., Han Q., Hermann T., Kissinger C.R., LeBrun L., Sergeeva M.V., and Kirkovsky L. Bioorg. Med. Chem. Lett. 18 (2008) 1413
5. Li L.-S., Zhou Y., Zhao J., Dragovich P.S., Stankovic N., Bertolini T.M., Murphy D.E., Sun Z., Tran C.V., Ayida B.K., Ruebsam F., and Webber S.E. Synthesis (2007) 3301
6. Murphy D.E., Dragovich P.S., Ayida B.K., Bertolini T.M., Li L.-S., Ruebsam F., Stankovic N.S., Sun Z., and Zhou Y. Tetrahedron Lett. 49 (2008) 811
7. 2-Amino-5-methoxy-benzenesulfonamide 4, benzothiadiazine acid 7 and its ethyl ester 8 were prepared using modified literature methods as described in. Fitch M.D., Evans K.A., Chai D., and Duffy K.J. Org. Lett. 7 (2005) 5521
8. Kovalenko S.N., Chernykh V.P., Shkarlat A.E., Ukrainets I.V., Gridasov V.I., and Rudnev S.A. Chem. Heterocycl. Comp. (Engl. Transl.) 34 (1999) 791
9. Detailed procedures for the synthesis of compounds 1 and 2 as well as their analytical data are described in Zhou, Y.; Li, L.-S.; Webber, S. E. WO06066079A2, 2006.
10. 1H NMR and LC-MS analysis (≥95% HPLC purity). They are arbitrarily drawn in one of the possible tautomer forms.
11. 50 data is 20% from the mean value.
12. The amounts of protein in replicon assay were much higher than that in the NS5B enzyme assay. In the 1b NS5B enzyme assay, there was 0.1 g/L bovine serum albumin, while in the replicon assay there was about 4 g/L of fetal bovine serum (FBS).
13. Pauwels F., Mostmans W., Quirynen L.M.M., Helm L.V.D., Boutton C.W., Rueff A.-S., Cleiren E., Raboisson P., Surleraux D., Nyanguile O., and Simmen K.A. J. Virol. 81 (2007) 6909
14. The co-crystal structures of 2a, 2m, and 2p bound to the NS5B protein are not shown.
15. 2 at pH 7.6, and 2q at a concentration of 3 mM. Diffraction data were collected to a resolution of 2.3 Å on beamline 14IDB at the Advanced Photon Source at Argonne National Laboratory. This crystal structure has been deposited in the Protein Databank (www.rcsb.org) with entry code 3BSA. Full details of structure determination are given in the PDB entry.
16. The O-atom at the 5-position of the pyridazin-3-one in Figure 3 was arbitrarily drawn in the protonated form. The precise extent of the protonation was not determined.
17. O'Donnell J.P., Dalvie D.K., Kalgutkar A.S., and Obach R.S. Drug Metab. Dispos. 31 (2003) 1369